Global Lung Cancer Vaccines - Market

Lung Cancer Vaccines - Comprehensive Study by Type (Preventive Lung Cancer Vaccines, Therapeutic Lung Cancer Vaccines), Application (Hospitals, Clinics, Pharmacies, Vaccines Centers, Other, End user), End User (Pediatric Population, Geriatric Population) Players and Region - Global Market Outlook to 2030

Lung Cancer Vaccines - Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Lung Cancer Vaccines -
Lung Cancer Vaccines are called biological response modifiers because they restore or stimulate the ability of the immune system to fight disease and infection, according to the National Cancer Institute. Lung cancer vaccines can help prevent cancer from developing that is preventive or prophylactic vaccines or helps in treating cancer once it has developed. Due to the favorable initiatives are taken by the World Health Organization and increasing awareness regarding lung cancer prevention and treatment there is increasing the opportunity for market growth, while some of the factors like side effects associated with the lung cancer vaccines and inadequate access to it is creating a hindrance for the market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is fragmented by key vendors who are focusing on the production of lung cancer vaccines, improving efficiency and shelf life. Growth opportunities can be captured by tracking the ongoing process improvement and financial flexibility to invest in optimal strategies Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Lung Cancer Vaccines - market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Ono Pharmaceutical (Japan), Boehringer Ingelheim (Germany), Eli Lily (United States), GlaxoSmithKline (United Kingdom), Cascadian Therapeutics, Inc (United States), Merck (United States), CureVac (Germany), PDC*line Pharma (France), Aduro BioTech Inc. (United States) and Amgen (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Astellas Pharma Inc (Japan), Bristol-Myers Squibb (United States) and Dendreon (United States).

Segmentation Overview
AMA Research has segmented the market of Global Lung Cancer Vaccines - market by Type (Preventive Lung Cancer Vaccines and Therapeutic Lung Cancer Vaccines), Application (Hospitals, Clinics, Pharmacies, Vaccines Centers, Other and End user) and Region.



On the basis of geography, the market of Lung Cancer Vaccines - has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Pediatric Population will boost the Lung Cancer Vaccines - market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technology Advancement in Lung Cancer Vaccines and Technological Advancement with the Innovations of Different Possible Therapies for Cancer

Market Growth Drivers:
Growing Government Support for Lung Cancer Vaccines Development, Increased Awareness about the Disease Prevention and Treatment and Rising Focus on Immunization Programs

Challenges:
Inadequate Access To Lung Cancer Vaccines, Adverse Effect of Lung Cancer Vaccines If Taken Without Prescription and High Cost Involved in Research and Development of Lung Cancer Vaccines

Restraints:
Side Effects Associated With Lung Cancer Vaccines Such As Redness and Pain At The Site of Injection, Fever, and Fatigue & Muscles Pains

Opportunities:
Rising Demand from Emerging Countries and World Health Organization (WHO) Favorable Initiatives

Market Leaders and their expansionary development strategies
In February 2024, AstraZeneca has concluded the acquisition of the US-based clinical-stage biopharmaceutical company Icosavax. The acquisition will strengthen AstraZeneca’s position in the respiratory syncytial virus (RSV) space and is expected to support the progression of IVX-A12, a Phase III-ready vaccine targeting both RSV and human metapneumovirus (hMPV).

The U.S. Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and ResearchExternal (CBER) is responsible for regulating vaccines in the United States. The sponsor of a new vaccine product follows a multi-step approval process which are "An Investigational New Drug application, Pre-licensure vaccine clinical trials, A Biologics License Application (BLA), Inspection of the manufacturing facility, Presentation of findings to FDA’s Vaccines and Related Biological Products Advisory Committee External (VRBPAC) and Usability testing of product labeling.

Key Target Audience
Hospitals and Clinics, Medical Research Laboratories, Drug Manufacturers and Suppliers, Academic Research Institutes, Academic Medical Centers and Universities, Research and Development (R&D) Companies and Business Research and Consulting Service Providers

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Preventive Lung Cancer Vaccines
  • Therapeutic Lung Cancer Vaccines
By Application
  • Hospitals
  • Clinics
  • Pharmacies
  • Vaccines Centers
  • Other
  • End user
By End User
  • Pediatric Population
  • Geriatric Population

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Government Support for Lung Cancer Vaccines Development
      • 3.2.2. Increased Awareness about the Disease Prevention and Treatment
      • 3.2.3. Rising Focus on Immunization Programs
    • 3.3. Market Challenges
      • 3.3.1. Inadequate Access To Lung Cancer Vaccines
      • 3.3.2. Adverse Effect of Lung Cancer Vaccines If Taken Without Prescription
      • 3.3.3. High Cost Involved in Research and Development of Lung Cancer Vaccines
    • 3.4. Market Trends
      • 3.4.1. Technology Advancement in Lung Cancer Vaccines
      • 3.4.2. Technological Advancement with the Innovations of Different Possible Therapies for Cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lung Cancer Vaccines -, by Type, Application, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Lung Cancer Vaccines - (Value)
      • 5.2.1. Global Lung Cancer Vaccines - by: Type (Value)
        • 5.2.1.1. Preventive Lung Cancer Vaccines
        • 5.2.1.2. Therapeutic Lung Cancer Vaccines
      • 5.2.2. Global Lung Cancer Vaccines - by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Pharmacies
        • 5.2.2.4. Vaccines Centers
        • 5.2.2.5. Other
        • 5.2.2.6. End user
      • 5.2.3. Global Lung Cancer Vaccines - by: End User (Value)
        • 5.2.3.1. Pediatric Population
        • 5.2.3.2. Geriatric Population
      • 5.2.4. Global Lung Cancer Vaccines - Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Lung Cancer Vaccines -: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ono Pharmaceutical (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boehringer Ingelheim (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lily (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cascadian Therapeutics, Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. CureVac (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. PDC*line Pharma (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Aduro BioTech Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Amgen (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Lung Cancer Vaccines - Sale, by Type, Application, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Lung Cancer Vaccines - (Value)
      • 7.2.1. Global Lung Cancer Vaccines - by: Type (Value)
        • 7.2.1.1. Preventive Lung Cancer Vaccines
        • 7.2.1.2. Therapeutic Lung Cancer Vaccines
      • 7.2.2. Global Lung Cancer Vaccines - by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Pharmacies
        • 7.2.2.4. Vaccines Centers
        • 7.2.2.5. Other
        • 7.2.2.6. End user
      • 7.2.3. Global Lung Cancer Vaccines - by: End User (Value)
        • 7.2.3.1. Pediatric Population
        • 7.2.3.2. Geriatric Population
      • 7.2.4. Global Lung Cancer Vaccines - Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lung Cancer Vaccines -: by Type(USD Million)
  • Table 2. Lung Cancer Vaccines - Preventive Lung Cancer Vaccines , by Region USD Million (2018-2023)
  • Table 3. Lung Cancer Vaccines - Therapeutic Lung Cancer Vaccines , by Region USD Million (2018-2023)
  • Table 4. Lung Cancer Vaccines -: by Application(USD Million)
  • Table 5. Lung Cancer Vaccines - Hospitals , by Region USD Million (2018-2023)
  • Table 6. Lung Cancer Vaccines - Clinics , by Region USD Million (2018-2023)
  • Table 7. Lung Cancer Vaccines - Pharmacies , by Region USD Million (2018-2023)
  • Table 8. Lung Cancer Vaccines - Vaccines Centers , by Region USD Million (2018-2023)
  • Table 9. Lung Cancer Vaccines - Other , by Region USD Million (2018-2023)
  • Table 10. Lung Cancer Vaccines - End user , by Region USD Million (2018-2023)
  • Table 11. Lung Cancer Vaccines -: by End User(USD Million)
  • Table 12. Lung Cancer Vaccines - Pediatric Population , by Region USD Million (2018-2023)
  • Table 13. Lung Cancer Vaccines - Geriatric Population , by Region USD Million (2018-2023)
  • Table 14. South America Lung Cancer Vaccines -, by Country USD Million (2018-2023)
  • Table 15. South America Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 16. South America Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 17. South America Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 18. Brazil Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 19. Brazil Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 20. Brazil Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 21. Argentina Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 22. Argentina Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 23. Argentina Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 24. Rest of South America Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 27. Asia Pacific Lung Cancer Vaccines -, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 31. China Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 32. China Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 33. China Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 34. Japan Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 35. Japan Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 36. Japan Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 37. India Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 38. India Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 39. India Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 40. South Korea Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 41. South Korea Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 42. South Korea Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 43. Taiwan Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 44. Taiwan Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 45. Taiwan Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 46. Australia Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 47. Australia Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 48. Australia Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 52. Europe Lung Cancer Vaccines -, by Country USD Million (2018-2023)
  • Table 53. Europe Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 54. Europe Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 55. Europe Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 56. Germany Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 57. Germany Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 58. Germany Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 59. France Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 60. France Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 61. France Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 62. Italy Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 63. Italy Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 64. Italy Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 65. United Kingdom Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 68. Netherlands Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 69. Netherlands Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 70. Netherlands Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 71. Rest of Europe Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 74. MEA Lung Cancer Vaccines -, by Country USD Million (2018-2023)
  • Table 75. MEA Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 76. MEA Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 77. MEA Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 78. Middle East Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 79. Middle East Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 80. Middle East Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 81. Africa Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 82. Africa Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 83. Africa Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 84. North America Lung Cancer Vaccines -, by Country USD Million (2018-2023)
  • Table 85. North America Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 86. North America Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 87. North America Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 88. United States Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 89. United States Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 90. United States Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 91. Canada Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 92. Canada Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 93. Canada Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 94. Mexico Lung Cancer Vaccines -, by Type USD Million (2018-2023)
  • Table 95. Mexico Lung Cancer Vaccines -, by Application USD Million (2018-2023)
  • Table 96. Mexico Lung Cancer Vaccines -, by End User USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Lung Cancer Vaccines -: by Type(USD Million)
  • Table 108. Lung Cancer Vaccines - Preventive Lung Cancer Vaccines , by Region USD Million (2025-2030)
  • Table 109. Lung Cancer Vaccines - Therapeutic Lung Cancer Vaccines , by Region USD Million (2025-2030)
  • Table 110. Lung Cancer Vaccines -: by Application(USD Million)
  • Table 111. Lung Cancer Vaccines - Hospitals , by Region USD Million (2025-2030)
  • Table 112. Lung Cancer Vaccines - Clinics , by Region USD Million (2025-2030)
  • Table 113. Lung Cancer Vaccines - Pharmacies , by Region USD Million (2025-2030)
  • Table 114. Lung Cancer Vaccines - Vaccines Centers , by Region USD Million (2025-2030)
  • Table 115. Lung Cancer Vaccines - Other , by Region USD Million (2025-2030)
  • Table 116. Lung Cancer Vaccines - End user , by Region USD Million (2025-2030)
  • Table 117. Lung Cancer Vaccines -: by End User(USD Million)
  • Table 118. Lung Cancer Vaccines - Pediatric Population , by Region USD Million (2025-2030)
  • Table 119. Lung Cancer Vaccines - Geriatric Population , by Region USD Million (2025-2030)
  • Table 120. South America Lung Cancer Vaccines -, by Country USD Million (2025-2030)
  • Table 121. South America Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 122. South America Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 123. South America Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 124. Brazil Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 125. Brazil Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 126. Brazil Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 127. Argentina Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 128. Argentina Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 129. Argentina Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 130. Rest of South America Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 131. Rest of South America Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 132. Rest of South America Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 133. Asia Pacific Lung Cancer Vaccines -, by Country USD Million (2025-2030)
  • Table 134. Asia Pacific Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 135. Asia Pacific Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 136. Asia Pacific Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 137. China Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 138. China Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 139. China Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 140. Japan Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 141. Japan Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 142. Japan Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 143. India Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 144. India Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 145. India Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 146. South Korea Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 147. South Korea Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 148. South Korea Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 149. Taiwan Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 150. Taiwan Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 151. Taiwan Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 152. Australia Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 153. Australia Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 154. Australia Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 155. Rest of Asia-Pacific Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 158. Europe Lung Cancer Vaccines -, by Country USD Million (2025-2030)
  • Table 159. Europe Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 160. Europe Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 161. Europe Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 162. Germany Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 163. Germany Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 164. Germany Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 165. France Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 166. France Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 167. France Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 168. Italy Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 169. Italy Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 170. Italy Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 171. United Kingdom Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 172. United Kingdom Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 173. United Kingdom Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 174. Netherlands Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 175. Netherlands Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 176. Netherlands Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 177. Rest of Europe Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 178. Rest of Europe Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 179. Rest of Europe Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 180. MEA Lung Cancer Vaccines -, by Country USD Million (2025-2030)
  • Table 181. MEA Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 182. MEA Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 183. MEA Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 184. Middle East Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 185. Middle East Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 186. Middle East Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 187. Africa Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 188. Africa Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 189. Africa Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 190. North America Lung Cancer Vaccines -, by Country USD Million (2025-2030)
  • Table 191. North America Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 192. North America Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 193. North America Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 194. United States Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 195. United States Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 196. United States Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 197. Canada Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 198. Canada Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 199. Canada Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 200. Mexico Lung Cancer Vaccines -, by Type USD Million (2025-2030)
  • Table 201. Mexico Lung Cancer Vaccines -, by Application USD Million (2025-2030)
  • Table 202. Mexico Lung Cancer Vaccines -, by End User USD Million (2025-2030)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lung Cancer Vaccines -: by Type USD Million (2018-2023)
  • Figure 5. Global Lung Cancer Vaccines -: by Application USD Million (2018-2023)
  • Figure 6. Global Lung Cancer Vaccines -: by End User USD Million (2018-2023)
  • Figure 7. South America Lung Cancer Vaccines - Share (%), by Country
  • Figure 8. Asia Pacific Lung Cancer Vaccines - Share (%), by Country
  • Figure 9. Europe Lung Cancer Vaccines - Share (%), by Country
  • Figure 10. MEA Lung Cancer Vaccines - Share (%), by Country
  • Figure 11. North America Lung Cancer Vaccines - Share (%), by Country
  • Figure 12. Global Lung Cancer Vaccines - share by Players 2023 (%)
  • Figure 13. Global Lung Cancer Vaccines - share by Players (Top 3) 2023(%)
  • Figure 14. Global Lung Cancer Vaccines - share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Ono Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 17. Ono Pharmaceutical (Japan) Revenue: by Geography 2023
  • Figure 18. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Boehringer Ingelheim (Germany) Revenue: by Geography 2023
  • Figure 20. Eli Lily (United States) Revenue, Net Income and Gross profit
  • Figure 21. Eli Lily (United States) Revenue: by Geography 2023
  • Figure 22. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 24. Cascadian Therapeutics, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 25. Cascadian Therapeutics, Inc (United States) Revenue: by Geography 2023
  • Figure 26. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 27. Merck (United States) Revenue: by Geography 2023
  • Figure 28. CureVac (Germany) Revenue, Net Income and Gross profit
  • Figure 29. CureVac (Germany) Revenue: by Geography 2023
  • Figure 30. PDC*line Pharma (France) Revenue, Net Income and Gross profit
  • Figure 31. PDC*line Pharma (France) Revenue: by Geography 2023
  • Figure 32. Aduro BioTech Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Aduro BioTech Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 35. Amgen (United States) Revenue: by Geography 2023
  • Figure 36. Global Lung Cancer Vaccines -: by Type USD Million (2025-2030)
  • Figure 37. Global Lung Cancer Vaccines -: by Application USD Million (2025-2030)
  • Figure 38. Global Lung Cancer Vaccines -: by End User USD Million (2025-2030)
  • Figure 39. South America Lung Cancer Vaccines - Share (%), by Country
  • Figure 40. Asia Pacific Lung Cancer Vaccines - Share (%), by Country
  • Figure 41. Europe Lung Cancer Vaccines - Share (%), by Country
  • Figure 42. MEA Lung Cancer Vaccines - Share (%), by Country
  • Figure 43. North America Lung Cancer Vaccines - Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Ono Pharmaceutical (Japan)
  • Boehringer Ingelheim (Germany)
  • Eli Lily (United States)
  • GlaxoSmithKline (United Kingdom)
  • Cascadian Therapeutics, Inc (United States)
  • Merck (United States)
  • CureVac (Germany)
  • PDC*line Pharma (France)
  • Aduro BioTech Inc. (United States)
  • Amgen (United States)
Additional players considered in the study are as follows:
Astellas Pharma Inc (Japan) , Bristol-Myers Squibb (United States) , Dendreon (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 243 Pages 61 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Lung Cancer Vaccines - Market Quantitative research analysis
Global Lung Cancer Vaccines - Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Ono Pharmaceutical (Japan), Boehringer Ingelheim (Germany), Eli Lily (United States), GlaxoSmithKline (United Kingdom), Cascadian Therapeutics, Inc (United States), Merck (United States), CureVac (Germany), PDC
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technology Advancement in Lung Cancer Vaccines " is seen as one of major influencing trends for Lung Cancer Vaccines - Market during projected period 2023-2030.
The Lung Cancer Vaccines - market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Lung Cancer Vaccines - Market Report?

Have a Query? Click Here

Other Related Reports

Knee Replacement Surgery Comprehensive Study by Type (Total Knee Replacement, Partial Knee Replacement, Kneecap Replacement, Complex/Revision Knee Replacement), Application (Hospitals, Ambulatory Sur...
$ 3450
Kidney Stone Therapy Comprehensive Study by Type (Non-invasive Therapy, Minimally Invasive Treatment, Others), Application (Clinic , Hospital , Others), Stone type (Calcium Oxalate Stones, Uric Acid,...
$ 3750
Urethral Stricture Comprehensive Study by Type (Posterior Urethral Stricture, Anterior Urethral Stricture), Application (Hospitals, Gastrointestinal Surgery Clinics, Ambulatory Surgical Centers, Othe...
$ 3750
Constipation Treatment Comprehensive Study by Application (Infants, Children), Medication (Opioids, Vitamin Supplements, Antiemetics, Drugs, Antacids, Diuretics), Constipation (Normal Transit Constip...
$ 3450
Bilirubin Blood Test Comprehensive Study by Type (Transcutaneous, Bench-top), Application (Disease Diagnose, Blood Routine Analysis, Disease Prevention, Others), End Use (Hospital, Clinic, Healthcare...
$ 3800
Clinical Laboratory Service Comprehensive Study by Application (Hematology, Urinalysis, Microbiology, Immunochemistry, Others), Tests (Blood Testing, Urine Testing, Oral Fluid Testing, Hair Testing, ...
$ 3450